A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis - Ports, W.C.; Khan, S.; Lan, S.; Lamba, M.; Bolduc, C.; Bissonnette, R.; Papp, K. (British journal of dermatology (1951), 2013)
Keywords: Administration, Cutaneous; Adult; Aged; Biological and medical sciences; Chronic Disease; Dermatologic Agents - administration & dosage; Dermatologic Agents - adverse effects; Dermatologic Agents - pharmacokinetics; Dermatology; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Medical sciences; Middle Aged; Ointments; Original; Piperidines - administration & dosage; Piperidines - adverse effects; Piperidines - pharmacokinetics; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - pharmacokinetics; Psoriasis - drug therapy; Psoriasis. Parapsoriasis. Lichen; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Pyrimidines - pharmacokinetics; Pyrroles - administration & dosage; Pyrroles - adverse effects; Pyrroles - pharmacokinetics; Treatment Outcome; Young Adult; Local administration; Skin disease; Chronic; Randomization; Phase; Treatment; Psoriasis; Dermatology; Tyrosine kinase inhibitor; Clinical trial; Safety